Uncategorized – Page 4

Science-Led Storytelling Takes Center Stage in Pharma Communications (June 2025)

6 days ago talkbio0Tagged Cheryl Lubbert, Engaged to be married, Pharma, pharmaceutical communications, Reverba Global, science-led storytelling, Translucent, Trust (Social Behavior)

pharmaceutical communications; science-led storytelling; pharma marketing; patient engagement; trust and transparency; Cheryl Lubbert; Reverba Global

Gilead Bolsters Trodelvy in Triple-Negative Breast Cancer With Practice-Changing Keytruda Combo Win

7 days ago talkbio0Tagged Antibody-Drug Conjugates, Combined Modality Therapy, Gilead Sciences, Immunotherapy, Keytruda, Phase 3 trial, practice-changing, Progression-Free Survival, TNBC, Triple Negative Breast Neoplasms, Trodelvy

Gilead Sciences; Trodelvy; Keytruda; triple-negative breast cancer; TNBC; antibody-drug conjugate; immunotherapy; progression-free survival; ASCO 2025; phase 3 trial; practice-changing; combination therapy

J&J’s Akeega Advances PARP Inhibition in Prostate Cancer, but FDA Pathway in Broader Patient Subsets Remains Unclear

7 days ago talkbio0Tagged Akeega, Amplitude, Approved, BRCA, HRR gene, Inhibitor, J&J, Malignant neoplasm of prostate, mCSPC, Metastatic castration-resistant prostate cancer, metastatic castration-sensitive prostate cancer, Mutation, PARP1 gene, United States Food and Drug Administration

Akeega; J&J; prostate cancer; PARP inhibitor; FDA approval; BRCA mutations; HRR gene alterations; AMPLITUDE study; metastatic castration-sensitive prostate cancer (mCSPC); metastatic castration-resistant prostate cancer (mCRPC)

Actuate Therapeutics’ Pancreatic Cancer Drug Elraglusib Shows Survival Benefit in Phase 2 Study

7 days ago talkbio0Tagged 130-nm albumin-bound paclitaxel, Actuate, ASCO, Elraglusib, gemcitabine, Metastatic Pancreatic Ductal Adenocarcinoma, Midline (qualifier value), Pancreatic carcinoma, Survival

Actuate Therapeutics; Elraglusib; Pancreatic cancer; Phase 2 trial; Median overall survival; Gemcitabine; Nab-paclitaxel; Metastatic pancreatic ductal adenocarcinoma; Survival benefit; ASCO 2025

BioAge Signs Option Agreement for Obesity Asset from Chinese Biotech Following APJ Agonist Setback

1 week ago talkbio0Tagged Agonist, APJ, BioAge, Exercise, incretin therapy, Metabolic Diseases, mimetics, nanobody, Obesity, small molecule agonists

BioAge; JiKang Therapeutics; obesity; APJ agonist; option agreement; nanobody; small molecule agonists; exercise mimetic; incretin therapy; metabolic diseases